Use of IL-31 monoclonal antibodies for treating neuronal inflammation
US9834602B2 · kind B2 · utility
0Cited by
35References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2017 |
| Grant date | Dec 5, 2017 |
| Priority date | — |
| Expiry date | Mar 15, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.